Trial Profile
An observational, retrospective study comparing risk of hypoglycemia with Toujeo with other basal insulins in type 2 diabetes patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Feb 2019
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary) ; Insulin degludec; Insulin detemir
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Acronyms DELIVER 2
- Sponsors Sanofi
- 07 Apr 2017 New trial record
- 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society
- 02 Apr 2017 Results presented at the Endocrine Society 2017 Annual Meeting (ENDO 2017), according to a Sanofi media release.